| Assessment Status | Rapid Review Complete |
| HTA ID | 24031 |
| Drug | Fruquintinib |
| Brand | Fruzaqla® |
| Indication | For the treatment of adult patients with metastatic colorectal cancer who have been previously treated with available standard therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan based chemotherapies, anti VEGF agents, and anti EGFR agents, and who have progressed on or are intolerant to treatment with either trifluridine tipiracil or regorafenib |
| Assessment Process | |
| Rapid review commissioned | 31/07/2024 |
| Rapid review completed | 16/09/2024 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of fruquintinib compared with the current standard of care, on the basis of the proposed price relative to currently available therapies. |
